2,035,790 Shares in BridgeBio Pharma (NASDAQ:BBIO) Bought by Hillhouse Capital Management LTD.

Share on StockTwits

Hillhouse Capital Management LTD. acquired a new position in shares of BridgeBio Pharma (NASDAQ:BBIO) in the 2nd quarter, HoldingsChannel.com reports. The fund acquired 2,035,790 shares of the company’s stock, valued at approximately $54,905,000. BridgeBio Pharma accounts for about 1.8% of Hillhouse Capital Management LTD.’s portfolio, making the stock its 13th largest position.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in BBIO. Alpine Group USVI LLC acquired a new position in shares of BridgeBio Pharma in the second quarter worth $539,000. SG Americas Securities LLC purchased a new stake in shares of BridgeBio Pharma in the second quarter valued at $476,000. Janus Henderson Group PLC purchased a new stake in shares of BridgeBio Pharma in the second quarter valued at $9,331,000. TimesSquare Capital Management LLC purchased a new stake in shares of BridgeBio Pharma in the second quarter valued at $4,046,000. Finally, JPMorgan Chase & Co. purchased a new stake in shares of BridgeBio Pharma in the second quarter valued at $25,274,000. 85.33% of the stock is owned by institutional investors.

In other news, major shareholder Genetic Disorder L.P. Kkr purchased 2,647,100 shares of the stock in a transaction on Monday, July 1st. The stock was purchased at an average price of $17.00 per share, with a total value of $45,000,700.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Brian C. Stephenson purchased 55,500 shares of the stock in a transaction on Monday, July 1st. The shares were purchased at an average cost of $17.00 per share, with a total value of $943,500.00. The disclosure for this purchase can be found here. In the last ninety days, insiders bought 7,409,500 shares of company stock valued at $125,947,930.

Shares of NASDAQ:BBIO opened at $26.27 on Friday. BridgeBio Pharma has a 52 week low of $24.06 and a 52 week high of $32.94. The firm has a fifty day simple moving average of $28.35.

A number of equities research analysts have recently commented on the company. Raymond James assumed coverage on BridgeBio Pharma in a research report on Friday, July 26th. They issued an “outperform” rating and a $36.00 price objective for the company. Leerink Swann assumed coverage on BridgeBio Pharma in a research report on Monday, July 22nd. They issued an “outperform” rating and a $34.00 price objective for the company. BMO Capital Markets assumed coverage on BridgeBio Pharma in a research report on Monday, July 22nd. They issued an “outperform” rating and a $49.00 price objective for the company. Svb Leerink assumed coverage on BridgeBio Pharma in a research report on Monday, July 22nd. They issued an “outperform” rating and a $34.00 price objective for the company. Finally, Jefferies Financial Group assumed coverage on BridgeBio Pharma in a research report on Monday, July 22nd. They issued a “buy” rating and a $38.00 price objective for the company. Eight equities research analysts have rated the stock with a buy rating, The stock currently has an average rating of “Buy” and an average price target of $40.13.

About BridgeBio Pharma

BridgeBio Pharma, Inc finds, develops, and delivers various medicines for genetic diseases. The company has a pipeline of 15 development programs that include product candidates ranging from early discovery to late-stage development in various therapeutic areas, including genetic dermatology, oncology, cardiology, neurology, endocrinology, renal disease, and ophthalmology.

Read More: Certificate of Deposit (CD)

Want to see what other hedge funds are holding BBIO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BridgeBio Pharma (NASDAQ:BBIO).

Institutional Ownership by Quarter for BridgeBio Pharma (NASDAQ:BBIO)

Receive News & Ratings for BridgeBio Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BridgeBio Pharma and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Keurig Dr Pepper  Upgraded to “Sell” at ValuEngine
Keurig Dr Pepper Upgraded to “Sell” at ValuEngine
Mobil’nye Telesistemy PAO  Downgraded by Zacks Investment Research to Sell
Mobil’nye Telesistemy PAO Downgraded by Zacks Investment Research to Sell
ArcelorMittal  Stock Rating Upgraded by Zacks Investment Research
ArcelorMittal Stock Rating Upgraded by Zacks Investment Research
Morgan Stanley Boosts Lockheed Martin  Price Target to $381.00
Morgan Stanley Boosts Lockheed Martin Price Target to $381.00
Scorpio Bulkers  Downgraded by ValuEngine to Strong Sell
Scorpio Bulkers Downgraded by ValuEngine to Strong Sell
Qudian  Receives New Coverage from Analysts at BOCOM International
Qudian Receives New Coverage from Analysts at BOCOM International


© 2006-2019 Ticker Report